New insider activity at Merck & Company ( (MRK) ) has taken place on February 8, 2025.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
In recent stock transactions involving Merck & Company, Chief Communications & Public Affairs Officer Cristal N. Downing sold 2,361 shares valued at $209,538. Meanwhile, Executive Chairman Inge Thulin made a purchase of 2,832 shares worth $249,924. Additionally, Executive Chairman of the Board Douglas M. Baker acquired 15,000 shares with a total investment of $1,327,500.
Recent Updates on MRK stock
Merck & Company’s stock has experienced notable price target reductions recently due to several challenges. Analysts cited the company’s below-consensus outlook and shifting expectations for its consistent product line as major concerns. Additionally, Merck’s decision to halt Gardasil vaccine shipments to China until inventories stabilize has brought renewed focus on challenges related to its Keytruda product. Despite strong financial performance in 2024, the market’s confidence appears shaken, prompting analysts to adjust their expectations. The company is seen as undervalued with potential for recovery, contingent on consistent achievement of guidance and positive developments such as approvals and data releases.
More about Merck & Company
YTD Price Performance: -11.21%
Average Trading Volume: 12,767,574
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $222.7B